CIK 0001029142
DVAX DYNAVAX TECHNOLOGIES CORP
Insider trading from SEC Form 4. Last filing Aug 25, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
16
with a Form 4 at this company
Signals
Open-market buys and sells at DYNAVAX TECHNOLOGIES CORP, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 24Weak | Scott Dunseth Myers director buy | $41k 3,800 shares | +12% | - | |
| 42Moderate | Deep Track Biotechnology Master Fund, Ltd. owner sell | $22M 2,065,137 shares | -12% | - | |
| 16Weak | David F Novack President & COO sell | $140k 10,000 shares | -55% | - | |
| 32Weak | David F Novack President & COO sell | $190k 14,020 shares | -63% | - | |
| 37Weak | David F Novack President & COO sell | $471k 32,764 shares | -60% | - |
Transactions
The last 93 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 22, 2025 | Scott Dunseth Myers director | POpen-market purchase Common Stock | +3,800 | $10.82 | $41k | 35,004 | Aug 25, 2025 |
| Aug 21, 2025 | Deep Track Biotechnology Master Fund, Ltd. owner | SOpen-market sale Common Stock, par value $0.001 per share | -1,094,994 | $11.03 | $12M | 16,696,492 | Aug 22, 2025 |
| Aug 22, 2025 | Deep Track Biotechnology Master Fund, Ltd. owner | SOpen-market sale Common Stock, par value $0.001 per share | -970,143 | $10.59 | $10M | 15,726,349 | Aug 22, 2025 |
| Jun 11, 2025 | Francis Cano director | AGrant or award Common Stock | +5,758 | $0.00 | $0 | 42,663 | Jun 13, 2025 |
| Jun 11, 2025 | Brent MacGregor director | AGrant or award Common Stock | +5,758 | $0.00 | $0 | 21,829 | Jun 13, 2025 |
| Jun 11, 2025 | Elaine D Sun director | AGrant or award Common Stock | +5,758 | $0.00 | $0 | 29,865 | Jun 13, 2025 |
| Jun 11, 2025 | Lauren P Silvernail director | AGrant or award Common Stock | +1,439 | $0.00 | $0 | 10,075 | Jun 13, 2025 |
| Jun 11, 2025 | Emilio Emini director | AGrant or award Common Stock | +1,439 | $0.00 | $0 | 10,075 | Jun 13, 2025 |
| Jun 11, 2025 | Peter R. Paradiso director | AGrant or award Common Stock | +5,758 | $0.00 | $0 | 24,829 | Jun 13, 2025 |
| Jun 11, 2025 | Daniel L Kisner director | AGrant or award Common Stock | +5,758 | $0.00 | $0 | 23,329 | Jun 13, 2025 |
| Jun 11, 2025 | Scott Dunseth Myers director | AGrant or award Common Stock | +5,758 | $0.00 | $0 | 31,204 | Jun 13, 2025 |
| Jun 11, 2025 | Francis Cano director | AGrant or award Stock Option (Right to Buy)derivative | +28,500 | $0.00 | $0 | 28,500 | Jun 13, 2025 |
| Jun 11, 2025 | Lauren P Silvernail director | AGrant or award Stock Option (Right to Buy)derivative | +7,125 | $0.00 | $0 | 7,125 | Jun 13, 2025 |
| Jun 11, 2025 | Daniel L Kisner director | AGrant or award Stock Option (Right to Buy)derivative | +28,500 | $0.00 | $0 | 28,500 | Jun 13, 2025 |
| Jun 11, 2025 | Scott Dunseth Myers director | AGrant or award Stock Option (Right to Buy)derivative | +28,500 | $0.00 | $0 | 28,500 | Jun 13, 2025 |
| Jun 11, 2025 | Peter R. Paradiso director | AGrant or award Stock Option (Right to Buy)derivative | +28,500 | $0.00 | $0 | 28,500 | Jun 13, 2025 |
| Jun 11, 2025 | Emilio Emini director | AGrant or award Stock Option (Right to Buy)derivative | +7,125 | $0.00 | $0 | 7,125 | Jun 13, 2025 |
| Jun 11, 2025 | Elaine D Sun director | AGrant or award Stock Option (Right to Buy)derivative | +28,500 | $0.00 | $0 | 28,500 | Jun 13, 2025 |
| Jun 11, 2025 | Brent MacGregor director | AGrant or award Stock Option (Right to Buy)derivative | +28,500 | $0.00 | $0 | 28,500 | Jun 13, 2025 |
| May 12, 2025 | Joseph Anthony Metzinger VP, Chief Accounting Officer | AGrant or award Option (Right
to Buy)derivative | +31,500 | - | - | 31,500 | May 13, 2025 |
| May 12, 2025 | Joseph Anthony Metzinger VP, Chief Accounting Officer | AGrant or award Restricted Stock Unitderivative | +38,182 | - | - | 38,182 | May 13, 2025 |
| Mar 24, 2025 | David F Novack President & COO | MOption exercise Common Stock10b5-1 | +10,000 | $6.81 | $68k | 18,078 | Mar 26, 2025 |
| Mar 24, 2025 | David F Novack President & COO | SOpen-market sale Common Stock10b5-1 | -10,000 | $14.00 | $140k | 8,078 | Mar 26, 2025 |
| Mar 24, 2025 | David F Novack President & COO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | - | - | 186,528 | Mar 26, 2025 |
| Mar 18, 2025 | David F Novack President & COO | SOpen-market sale Common Stock10b5-1 | -14,020 | $13.58 | $190k | 8,078 | Mar 20, 2025 |
| Mar 7, 2025 | David F Novack President & COO | SOpen-market sale Common Stock10b5-1 | -32,764 | $14.39 | $471k | 22,098 | Mar 10, 2025 |
| Feb 18, 2025 | John L Slebir SVP General Counsel | MOption exercise Common Stock | +16,667 | - | - | 41,731 | Feb 21, 2025 |
| Feb 18, 2025 | John L Slebir SVP General Counsel | FTax withholding Common Stock | -5,358 | $12.93 | $69k | 36,373 | Feb 21, 2025 |
| Feb 18, 2025 | John L Slebir SVP General Counsel | MOption exercise Restricted Stock Unitderivative | -16,667 | - | - | 33,333 | Feb 21, 2025 |
| Feb 18, 2025 | Ryan Spencer CEO and Director | MOption exercise Common Stock | +55,000 | - | - | 297,261 | Feb 20, 2025 |
| Feb 18, 2025 | Kelly MacDonald SVP and CFO | MOption exercise Common Stock | +15,477 | - | - | 34,202 | Feb 20, 2025 |
| Feb 18, 2025 | Robert Janssen SVP and CMO | MOption exercise Common Stock | +11,904 | - | - | 81,526 | Feb 20, 2025 |
| Feb 18, 2025 | David F Novack President & COO | MOption exercise Common Stock | +22,620 | - | - | 65,527 | Feb 20, 2025 |
| Feb 18, 2025 | David F Novack President & COO | FTax withholding Common Stock | -10,665 | $12.93 | $138k | 54,862 | Feb 20, 2025 |
| Feb 18, 2025 | Ryan Spencer CEO and Director | FTax withholding Common Stock | -36,528 | $12.93 | $472k | 260,733 | Feb 20, 2025 |
| Feb 18, 2025 | Kelly MacDonald SVP and CFO | FTax withholding Common Stock | -4,975 | $12.93 | $64k | 29,227 | Feb 20, 2025 |
| Feb 18, 2025 | Robert Janssen SVP and CMO | FTax withholding Common Stock | -4,041 | $12.93 | $52k | 77,485 | Feb 20, 2025 |
| Feb 18, 2025 | Kelly MacDonald SVP and CFO | MOption exercise Restricted Stock Unitderivative | -15,477 | - | - | 30,953 | Feb 20, 2025 |
| Feb 18, 2025 | Robert Janssen SVP and CMO | MOption exercise Restricted Stock Unitderivative | -11,904 | - | - | 23,806 | Feb 20, 2025 |
| Feb 18, 2025 | Ryan Spencer CEO and Director | MOption exercise Restricted Stock Unitderivative | -55,000 | - | - | 110,000 | Feb 20, 2025 |
| Feb 18, 2025 | David F Novack President & COO | MOption exercise Restricted Stock Unitderivative | -22,620 | - | - | 45,240 | Feb 20, 2025 |
| Feb 13, 2025 | Robert Janssen SVP and CMO | MOption exercise Common Stock | +13,000 | - | - | 74,236 | Feb 18, 2025 |
| Feb 13, 2025 | Ryan Spencer CEO and Director | MOption exercise Common Stock | +62,500 | - | - | 273,522 | Feb 18, 2025 |
| Feb 13, 2025 | Kelly MacDonald SVP and CFO | MOption exercise Common Stock | +16,000 | - | - | 24,043 | Feb 18, 2025 |
| Feb 13, 2025 | John L Slebir SVP General Counsel | MOption exercise Common Stock | +14,000 | - | - | 28,397 | Feb 18, 2025 |
| Feb 13, 2025 | David F Novack President & COO | MOption exercise Common Stock | +26,500 | - | - | 54,156 | Feb 18, 2025 |
| Feb 13, 2025 | Robert Janssen SVP and CMO | FTax withholding Common Stock | -4,614 | $12.69 | $59k | 69,622 | Feb 18, 2025 |
| Feb 13, 2025 | Ryan Spencer CEO and Director | FTax withholding Common Stock | -31,694 | $12.69 | $402k | 242,261 | Feb 18, 2025 |
| Feb 13, 2025 | Kelly MacDonald SVP and CFO | FTax withholding Common Stock | -5,318 | $12.69 | $67k | 18,725 | Feb 18, 2025 |
| Feb 13, 2025 | John L Slebir SVP General Counsel | FTax withholding Common Stock | -4,708 | $12.69 | $60k | 25,064 | Feb 18, 2025 |
| Feb 13, 2025 | David F Novack President & COO | FTax withholding Common Stock | -12,480 | $12.69 | $158k | 42,907 | Feb 18, 2025 |
| Feb 13, 2025 | Ryan Spencer CEO and Director | AGrant or award Restricted Stock Unitderivative | +62,500 | - | - | 62,500 | Feb 18, 2025 |
| Feb 13, 2025 | John L Slebir SVP General Counsel | AGrant or award Restricted Stock Unitderivative | +14,000 | - | - | 14,000 | Feb 18, 2025 |
| Feb 13, 2025 | David F Novack President & COO | AGrant or award Restricted Stock Unitderivative | +26,500 | - | - | 26,500 | Feb 18, 2025 |
| Feb 13, 2025 | Kelly MacDonald SVP and CFO | AGrant or award Restricted Stock Unitderivative | +16,000 | - | - | 16,000 | Feb 18, 2025 |
| Feb 13, 2025 | Robert Janssen SVP and CMO | AGrant or award Restricted Stock Unitderivative | +13,000 | - | - | 13,000 | Feb 18, 2025 |
| Feb 13, 2025 | David F Novack President & COO | MOption exercise Restricted Stock Unitderivative | -26,500 | - | - | 0 | Feb 18, 2025 |
| Feb 13, 2025 | Kelly MacDonald SVP and CFO | MOption exercise Restricted Stock Unitderivative | -16,000 | - | - | 0 | Feb 18, 2025 |
| Feb 13, 2025 | John L Slebir SVP General Counsel | MOption exercise Restricted Stock Unitderivative | -14,000 | - | - | 0 | Feb 18, 2025 |
| Feb 13, 2025 | Ryan Spencer CEO and Director | MOption exercise Restricted Stock Unitderivative | -62,500 | - | - | 0 | Feb 18, 2025 |
| Feb 13, 2025 | Robert Janssen SVP and CMO | MOption exercise Restricted Stock Unitderivative | -13,000 | - | - | 0 | Feb 18, 2025 |
| Feb 13, 2025 | Kelly MacDonald SVP and CFO | AGrant or award Stock Option (Right to Buy)derivative | +70,000 | - | - | 70,000 | Feb 18, 2025 |
| Feb 13, 2025 | David F Novack President & COO | AGrant or award Stock Option (Right to Buy)derivative | +93,000 | - | - | 93,000 | Feb 18, 2025 |
| Feb 13, 2025 | Ryan Spencer CEO and Director | AGrant or award Stock Option (Right to Buy)derivative | +225,000 | - | - | 225,000 | Feb 18, 2025 |
| Feb 13, 2025 | Robert Janssen SVP and CMO | AGrant or award Stock Options (Right to Buy)derivative | +55,000 | - | - | 55,000 | Feb 18, 2025 |
| Feb 13, 2025 | John L Slebir SVP General Counsel | AGrant or award Stock Option (Right to Buy)derivative | +70,000 | - | - | 70,000 | Feb 18, 2025 |
| Feb 13, 2025 | Ryan Spencer CEO and Director | AGrant or award Restricted Stock Unitderivative | +136,000 | - | - | 136,000 | Feb 18, 2025 |
| Feb 13, 2025 | Robert Janssen SVP and CMO | AGrant or award Restricted Stock Unitderivative | +33,333 | - | - | 33,333 | Feb 18, 2025 |
| Feb 13, 2025 | David F Novack President & COO | AGrant or award Restricted Stock Unitderivative | +56,364 | - | - | 56,364 | Feb 18, 2025 |
| Feb 13, 2025 | Kelly MacDonald SVP and CFO | AGrant or award Restricted Stock Unitderivative | +42,424 | - | - | 42,424 | Feb 18, 2025 |
| Feb 13, 2025 | John L Slebir SVP General Counsel | AGrant or award Restricted Stock Unitderivative | +42,424 | - | - | 42,424 | Feb 18, 2025 |
| Feb 10, 2025 | Ryan Spencer CEO and Director | MOption exercise Common Stock | +20,833 | - | - | 222,231 | Feb 12, 2025 |
| Feb 10, 2025 | David F Novack President & COO | MOption exercise Common Stock | +8,833 | - | - | 32,174 | Feb 12, 2025 |
| Feb 10, 2025 | John L Slebir SVP General Counsel | MOption exercise Common Stock | +4,666 | - | - | 16,144 | Feb 12, 2025 |
| Feb 10, 2025 | Kelly MacDonald SVP and CFO | MOption exercise Common Stock | +5,333 | - | - | 10,040 | Feb 12, 2025 |
| Feb 10, 2025 | Robert Janssen SVP and CMO | MOption exercise Common Stock | +4,333 | - | - | 63,017 | Feb 12, 2025 |
| Feb 10, 2025 | Justin Burgess VP Finance & CAO | MOption exercise Common Stock | +6,666 | - | - | 6,666 | Feb 12, 2025 |
| Feb 10, 2025 | Robert Janssen SVP and CMO | FTax withholding Common Stock | -1,781 | $13.20 | $24k | 61,236 | Feb 12, 2025 |
| Feb 10, 2025 | Kelly MacDonald SVP and CFO | FTax withholding Common Stock | -1,997 | $13.20 | $26k | 8,043 | Feb 12, 2025 |
| Feb 10, 2025 | David F Novack President & COO | FTax withholding Common Stock | -4,518 | $13.20 | $60k | 27,656 | Feb 12, 2025 |
| Feb 10, 2025 | Ryan Spencer CEO and Director | FTax withholding Common Stock | -11,209 | $13.20 | $148k | 211,022 | Feb 12, 2025 |
| Feb 10, 2025 | Justin Burgess VP Finance & CAO | FTax withholding Common Stock | -2,496 | $13.20 | $33k | 4,170 | Feb 12, 2025 |
| Feb 10, 2025 | John L Slebir SVP General Counsel | FTax withholding Common Stock | -1,747 | $13.20 | $23k | 14,397 | Feb 12, 2025 |
| Feb 10, 2025 | Robert Janssen SVP and CMO | MOption exercise Restricted Stock Unitderivative | -4,333 | - | - | 0 | Feb 12, 2025 |
| Feb 10, 2025 | David F Novack President & COO | MOption exercise Restricted Stock Unitderivative | -8,833 | - | - | 0 | Feb 12, 2025 |
| Feb 10, 2025 | John L Slebir SVP General Counsel | MOption exercise Restricted Stock Unitderivative | -4,666 | - | - | 0 | Feb 12, 2025 |
| Feb 10, 2025 | Ryan Spencer CEO and Director | MOption exercise Restricted Stock Unitderivative | -20,833 | - | - | 0 | Feb 12, 2025 |
| Feb 10, 2025 | Justin Burgess VP Finance & CAO | MOption exercise Restricted Stock Unitderivative | -6,666 | - | - | 0 | Feb 12, 2025 |
| Feb 10, 2025 | Kelly MacDonald SVP and CFO | MOption exercise Restricted Stock Unitderivative | -5,333 | - | - | 0 | Feb 12, 2025 |
| Feb 3, 2025 | Emilio Emini director | AGrant or award Stock Option (Right to Buy)derivative | +42,750 | $0.00 | $0 | 42,750 | Feb 5, 2025 |
| Feb 3, 2025 | Lauren P Silvernail director | AGrant or award Restricted Stock Unitderivative | +8,636 | - | - | 8,636 | Feb 5, 2025 |
| Feb 3, 2025 | Emilio Emini director | AGrant or award Restricted Stock Unitderivative | +8,636 | - | - | 8,636 | Feb 5, 2025 |
| Feb 3, 2025 | Lauren P Silvernail director | AGrant or award Stock Option (Right to Buy)derivative | +42,750 | $0.00 | $0 | 42,750 | Feb 5, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Justin BurgessVP Finance & CAO
- Francis Canodirector
- Deep Track Biotechnology Master Fund, Ltd.owner
- Emilio Eminidirector
- Robert JanssenSVP and CMO
- Daniel L Kisnerdirector
- Kelly MacDonaldSVP and CFO
- Brent MacGregordirector
- Joseph Anthony MetzingerVP, Chief Accounting Officer
- Scott Dunseth Myersdirector
- David F NovackPresident & COO
- Peter R. Paradisodirector
- Lauren P Silvernaildirector
- John L SlebirSVP General Counsel
- Ryan SpencerCEO and Director
- Elaine D Sundirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.